The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ozagrelum     (E)-3-[4-(imidazol-1- ylmethyl)phenyl]prop...

Synonyms: ozagrel, Cataclot (TN), SureCN4210, CHEMBL11662, S2496_Selleck, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ozagrel


Psychiatry related information on ozagrel

  • The reduced spontaneously locomotor activity and the obstruction of motor coordination were improved by the administration of ozagrel in the conscious cerebral ischemia-reperfusion mouse model [6].

High impact information on ozagrel


Chemical compound and disease context of ozagrel


Biological context of ozagrel

  • In the ozagrel-treated group, changes in plasma TXB(2) concentration, BE, HCO(3) (-), and platelet count were significantly inhibited [15].
  • Due to rapid and complete absorption (i.e., Tmax; 20 min, bioavailability; 100%) and longer duration of pharmacological action after rectal dosing, the rectum offers a practical delivery route for ozagrel [16].
  • In addition, ozagrel, GF109203X and Y27632 possessed no appreciable effects on the cell growth by themselves [17].

Anatomical context of ozagrel

  • Ozagrel was partly metabolized to M2 and M1 in rat intestinal mucosa, although the main metabolic site might be in the liver [10].
  • The blood flows around the infarcted area, in the cerebral cortex, and in the cerebral white matter were significantly increased by the administration of sodium ozagrel [4].
  • In 4 patients who had ACh-induced coronary spasm of the left anterior descending artery, the TXB2 concentration in the coronary sinus decreased after intracoronary administration of Ozagrel Na into the left coronary artery (463 +/- 562 vs 96 +/- 45, p < 0.01) [13].
  • Ozagrel did not alter the intracellular ROS or superoxide production of neutrophils [18].
  • Since the suture-induced MCAO model and the microthrombosis model are models for occlusion-reperfusion of the major cerebral arteries and lacunar infarction, respectively, these results suggest a highly beneficial effect of ozagrel in the clinical therapy for stroke [12].

Associations of ozagrel with other chemical compounds


Gene context of ozagrel


Analytical, diagnostic and therapeutic context of ozagrel


  1. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. Kawano, K.I., Fujishima, K., Ikeda, Y., Kondo, K., Umemura, K. J. Cereb. Blood Flow Metab. (2000) [Pubmed]
  2. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Kaku, S., Kawasaki, T., Hisamichi, N., Sakai, Y., Taniuchi, Y., Inagaki, O., Yano, S., Suzuki, K., Terazaki, C., Masuho, Y., Satoh, N., Takenaka, T., Yanagi, K., Ohshima, N. Thromb. Haemost. (1996) [Pubmed]
  3. Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. Ohyama, H., Hosomi, N., Takahashi, T., Mizushige, K., Kohno, M. Brain Res. (2001) [Pubmed]
  4. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction. Oishi, M., Mochizuki, Y., Hara, M., Yoshihashi, H., Takasu, T. Clinical neuropharmacology. (1996) [Pubmed]
  5. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Seki, H., Kuromaki, K., Takeda, S., Kinoshita, K., Satoh, K. Hypertension in pregnancy : official journal of the International Society for the Study of Hypertension in Pregnancy. (1999) [Pubmed]
  6. Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Ichikawa, K., Tazawa, S., Hamano, S., Kojima, M., Hiraku, S. Pharmacology (1999) [Pubmed]
  7. Involvement of thromboxane A2 and histamine in experimental allergic rhinitis of guinea pigs. Yamasaki, M., Matsumoto, T., Fukuda, S., Nakayama, T., Nagaya, H., Ashida, Y. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  8. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig. Moriguchi, A., Mihara, K., Aoki, T., Maeda, M., Tojo, N., Matsuoka, N., Mutoh, S. Eur. J. Pharmacol. (2004) [Pubmed]
  9. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding. Kawano, K.I., Hokamura, K., Kondo, K., Ikeda, Y., Suzuki, Y., Umemura, K. Eur. J. Pharmacol. (2001) [Pubmed]
  10. Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations. Ogiso, T., Iwaki, M., Hara, Y., Tanino, T. Journal of pharmaceutical sciences. (1997) [Pubmed]
  11. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Terashita, Z., Imura, Y., Kawamura, M., Kato, K., Nishikawa, K. Thromb. Res. (1995) [Pubmed]
  12. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. Imamura, T., Kiguchi, S., Kobayashi, K., Ichikawa, K., Yamazaki, Y., Kojima, M. Arzneimittel-Forschung. (2003) [Pubmed]
  13. Intracoronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholine-induced coronary spasm. Sueda, S., Kohno, H., Inoue, K., Fukuda, H., Suzuki, J., Watanabe, K., Ochi, N., Kawada, H., Uraoka, T. Circ. J. (2002) [Pubmed]
  14. Beneficial effect of combination therapy with ozagrel and pranlukast in exercise-induced asthma demonstrated by krypton-81 m ventilation scintigraphy--a case report. Takahashi, N., Ishibashi, Y., Murakami, Y., Shimizu, H., Ohta, Y., Asanuma, T., Katoh, H., Sano, K., Shimada, T. Ann. Acad. Med. Singap. (2000) [Pubmed]
  15. Effect of a selective thromboxane A(2) synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A(2). Motoyoshi, M., Sugiyama, M., Atomi, Y., Kimura, W., Nagawa, H. J. Gastroenterol. (2006) [Pubmed]
  16. Pharmacokinetic and pharmacodynamic studies of a thromboxane synthetase inhibitor, ozagrel, in rabbits. Zheng, N.X., Sato, H., Adachi, I., Kanamoto, I., Horikoshi, I. Biol. Pharm. Bull. (1995) [Pubmed]
  17. Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203X and Y27632 on cultured basilar artery smooth muscle cells. Yamaguchi, T., Oishi, K., Uchida, M., Echizen, H. Biol. Pharm. Bull. (2003) [Pubmed]
  18. Edaravone diminishes free radicals from circulating neutrophils in patients with ischemic brain attack. Aizawa, H., Makita, Y., Sumitomo, K., Aburakawa, Y., Katayama, T., Nakatani-Enomoto, S., Suzuki, Y., Fujiwara, K., Enomoto, H., Kuroda, K., Kimura, T., Yahara, O., Koyama, S., Maruyama, J., Nakamura, M., Hasebe, N., Kikuchi, K. Intern. Med. (2006) [Pubmed]
  19. Origin of thromboxane-mediated constriction due to neuropeptides in canine basilar artery. Tsuji, T., Cook, D.A. Eur. J. Pharmacol. (1994) [Pubmed]
  20. Ibuprofen or ozagrel increases NO release and l-nitro arginine induces TXA(2) release from cultured porcine basilar arterial endothelial cells. Miyamoto, A., Hashiguchi, Y., Obi, T., Ishiguro, S., Nishio, A. Vascul. Pharmacol. (2007) [Pubmed]
  21. Liberation of vasoactive substances and its prevention with thromboxane A2 synthase inhibitor in pig liver transplantation. Yokoyama, I., Kobayashi, T., Negita, M., Hayashi, S., Yasutomi, M., Katayama, A., Uchida, K., Takagi, H. Transpl. Int. (1996) [Pubmed]
  22. Effect of ozagrel hydrochloride, a thromboxane synthetase inhibitor, on alcoholic beverage-induced bronchoconstriction in asthmatic patients. Myou, S., Fujimura, M., Nishi, K., Kita, T., Kurashima, K., Tachibana, H., Ishiura, Y., Nakao, S. Prostaglandins Leukot. Essent. Fatty Acids (2002) [Pubmed]
  23. Rectal absorption of ozagrel from a suppository containing its commercial tablet in healthy human subjects. Zheng, N.X., Sato, H., Kobayashi, F., Masuko, Y., Adachi, I., Horikoshi, I. Biol. Pharm. Bull. (1997) [Pubmed]
WikiGenes - Universities